Friday 03 May 2024
Internal Reference Number: FOI_7249
Date Request Received: 19/06/2023 00:00:00
Date Request Replied To: 21/06/2023 00:00:00
This response was sent via: By Email
Request Summary: Melanoma & RCC
Request Category: Researcher
| Question Number 1: How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma : • Avelumab + Axitinib • Axinitib • Cabozantinib • Everolimus • Ipilimumab montherapy • Lenvantinib + Everolimus • Nivolumab monotherapy • Nivolumab + Cabozantinib • Nivolumab + Ipilimumab • Pazopanib • Pembrolizumab + Axitinib • Pembrolizumab + Lenvatinib • Pembrolizumab monotherapy • Radiotherapy only • Sunitinib • Temsirolimus • Tivozanib • Other active systemic anti-cancer therapy • Palliative care only | |
| Answer To Question 1: We do not treat these tumour groups at this Trust, patients receive their treatment at UHS. | |
| Question Number 2: How many patients have been treated in the past 3 months with the following agents for melanoma (any stage) : • Cobimetinib • Dabrafenib • Dabrafenib AND Trametinib • Dacarbazine • Encorafenib AND Binimetinib • Ipilimumab • Ipilimumab AND Nivolumab • Nivolumab • Pembrolizumab • Trametinib • Vemurafenib • Vemurafenib AND Cobimetinib • Other active systemic anti-cancer therapy • Palliative care only | |
| Answer To Question 2: We do not treat these tumour groups at this Trust, patients receive their treatment at UHS. | |
| Question Number 3: Does you trust participate in any clinical trials for the treatment of Melanoma? If so please provide the name of each trial and number of patients that are taking part? | |
| Answer To Question 3: No n/a | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
